Trial Profile

Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 07 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vamorolone (Primary)
Indications Duchenne muscular dystrophy
Focus Adverse reactions; Therapeutic Use
Acronyms SUMMIT
Sponsors Catalyst Pharmaceuticals

Most Recent Events

27 Feb 2026 "Presence of cardiomyopathy" added as a new primary end-point.
27 Feb 2026 Planned End Date changed from 1 Nov 2030 to 1 Feb 2032.
27 Feb 2026 Planned primary completion date changed from 1 Sep 2030 to 1 Feb 2032.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com